Tech Transfer Package Authoring
Assemble a complete pharmaceutical tech transfer package in three phases — Process & Manufacturing, Analytical & Specifications, Stability & Risk & Regulatory — with Executive Summary, Bill of Materials, Compendial References, Finished Product Specs, QTPP, ICH Q5E comparability protocol, ICH Q9(R1) FMEA risk register, and Gantt timeline anchored to today plus seven.
Short answer. Pure Monograph's Tech Transfer module produces the full audit-defensible documentation package a sending and receiving site need to move a product line. Every deliverable is anchored to current ICH / USP / 21 CFR / WHO references, and every timeline is calculated forward from today plus seven days — no stale kickoff dates.
What the package includes
- Executive Summary (400-600 words): API, form, sending and receiving site, sharpest technical risk, go-live target date anchored to kickoff.
- QTPP table per ICH Q8(R2) §2.1 with attribute-justification linkage to CQAs.
- Bill of Materials: component, INN, grade (USP-NF / Ph. Eur. / multi-compendial), function, quantity, % w/w, overages, storage.
- Compendial References: article, compendium, monograph / chapter, revision in force.
- Process description per ICH Q11 (drug substance) and CMC conventions for drug product, unit operations, IPCs, yield targets.
- CPP / CQA linkage table (min 10 CQAs × 12 CPPs) with impact / detectability scoring.
- Equipment and facility delta: side-by-side sending vs receiving equipment, utility differences, gap actions.
- Comparability Protocol per ICH Q5E: attributes, acceptance criteria, statistical approach (TOST / equivalence bounds), decision rules.
- Analytical method transfer plan per USP <1224> and ICH Q2(R2)/Q14.
- Finished Product Specifications: release and shelf-life limits side by side, 10+ rows covering appearance, identification, assay, impurities, dissolution, content uniformity, water content, microbial limits (USP <61>/<62>), particulate matter for injectables.
- Stability protocol per ICH Q1A(R2) / Q1D / Q1E — storage conditions, bracketing/matrixing, shelf-life projection.
- ICH Q9(R1) FMEA risk register: Severity × Occurrence × Detectability → RPN, mitigation, residual RPN, owner. Minimum 12 rows across CMC, analytical, regulatory, supply, clinical, HSE.
- Regulatory filing strategy per market: FDA CBE-30/PAS, EMA Type IA/IB/II, Health Canada Notifiable Change / Supplemental Notifiable Change.
- Gantt timeline: 25+ rows from initiation through closure, critical path annotated, every start date calculated forward from today plus seven.
What it does NOT do
- It does not replace on-site site qualification, equipment IQ/OQ/PQ, or exhibit-batch manufacture.
- It does not sign Quality Agreements between sponsor and receiving site.
- It does not audit your data integrity controls (that is a GxP audit scope).
Reference basis
ICH Q1 (2025 revision) for stability, Q2(R2)/Q14 (in force 2025) for analytical validation, Q5E for comparability, Q7 section 6.5 for API batch records, Q8(R2) for pharmaceutical development, Q9(R1) for risk, Q10 for PQS, Q11 for drug substance, Q12 for lifecycle management, Q13 for continuous manufacturing, M4Q(R2) 2025 for Module 3 alignment, M7(R2) for mutagenic impurities, 21 CFR 210/211/820, USP General Chapters, WHO Technical Report Series 961 Annex 7 (transfer of technology), and the ISPE Good Practice Guide: Technology Transfer.
Frequently asked questions
What is included in a tech transfer package?
Three phases: Process & Manufacturing (QTPP, process description, equipment delta, comparability protocol); Analytical & Specifications (method transfer, specs, validation, QC release); Stability, Risk & Regulatory (stability protocol, FMEA risk register, filing strategy, Gantt timeline).
How is the timeline anchored?
Project kickoff anchors at today plus seven calendar days. No past dates; no bare-year references in body text. Downstream milestones calculate forward from the kickoff anchor.
Which regulatory references does it cite?
ICH Q1-Q13, M4Q(R2), M7(R2), FDA 2025 draft CMC guidances, EMA 2025 Annex 1 for sterile, current USP revision, 21 CFR 210/211/820. WHO TRS 961 Annex 7 and the ISPE Good Practice Guide: Technology Transfer are referenced where relevant.
Is this a replacement for a site qualification?
No. The package generates documentation and a risk-ranked playbook. Real site qualification requires on-site audits, IQ/OQ/PQ, PPQ, and successful exhibit-batch manufacture. The sponsor and receiving site execute.